Click for best price
Hormone Refractory Prostate Cancer Market Size, Share 2022
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
This report contains market size and forecasts of Hormone Refractory Prostate Cancer in Global, including the following market information:
Global Hormone Refractory Prostate Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hormone Refractory Prostate Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hormone Refractory Prostate Cancer include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hormone Refractory Prostate Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hormone Refractory Prostate Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, by Type, 2021 (%)
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Global Hormone Refractory Prostate Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, by Application, 2021 (%)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Global Hormone Refractory Prostate Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hormone Refractory Prostate Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hormone Refractory Prostate Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
| Report Attributes |
Report Details |
| Report Title |
Hormone Refractory Prostate Cancer Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hormone Refractory Prostate Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hormone Refractory Prostate Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hormone Refractory Prostate Cancer Overall Market Size
2.1 Global Hormone Refractory Prostate Cancer Market Size: 2021 VS 2028
2.2 Global Hormone Refractory Prostate Cancer Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hormone Refractory Prostate Cancer Players in Global Market
3.2 Top Global Hormone Refractory Prostate Cancer Companies Ranked by Revenue
3.3 Global Hormone Refractory Prostate Cancer Revenue by Companies
3.4 Top 3 and Top 5 Hormone Refractory Prostate Cancer Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hormone Refractory Prostate Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hormone Refractory Prostate Cancer Players in Global Market
3.6.1 List of Global Tier 1 Hormone Refractory Prostate Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Hormone Refractory Prostate Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hormone Refractory Prostate Cancer Market Size Markets, 2021 & 2028
4.1.2 Chemotherapy
4.1.3 Hormonal Therapy
4.1.4 Immunotherapy
4.1.5 Radiation Therapy
4.2 By Type - Global Hormone Refractory Prostate Cancer Revenue & Forecasts
4.2.1 By Type - Global Hormone Refractory Prostate Cancer Revenue, 2017-2022
4.2.2 By Type - Global Hormone Refractory Prostate Cancer Revenue, 2023-2028
4.2.3 By Type - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hormone Refractory Prostate Cancer Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Specialty Clinics
5.2 By Application - Global Hormone Refractory Prostate Cancer Revenue & Forecasts
5.2.1 By Application - Global Hormone Refractory Prostate Cancer Revenue, 2017-2022
5.2.2 By Application - Global Hormone Refractory Prostate Cancer Revenue, 2023-2028
5.2.3 By Application - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hormone Refractory Prostate Cancer Market Size, 2021 & 2028
6.2 By Region - Global Hormone Refractory Prostate Cancer Revenue & Forecasts
6.2.1 By Region - Global Hormone Refractory Prostate Cancer Revenue, 2017-2022
6.2.2 By Region - Global Hormone Refractory Prostate Cancer Revenue, 2023-2028
6.2.3 By Region - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hormone Refractory Prostate Cancer Revenue, 2017-2028
6.3.2 US Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.3.3 Canada Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.3.4 Mexico Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hormone Refractory Prostate Cancer Revenue, 2017-2028
6.4.2 Germany Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.3 France Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.4 U.K. Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.5 Italy Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.6 Russia Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.7 Nordic Countries Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.4.8 Benelux Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hormone Refractory Prostate Cancer Revenue, 2017-2028
6.5.2 China Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.5.3 Japan Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.5.4 South Korea Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.5.5 Southeast Asia Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.5.6 India Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hormone Refractory Prostate Cancer Revenue, 2017-2028
6.6.2 Brazil Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.6.3 Argentina Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hormone Refractory Prostate Cancer Revenue, 2017-2028
6.7.2 Turkey Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.7.3 Israel Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.7.4 Saudi Arabia Hormone Refractory Prostate Cancer Market Size, 2017-2028
6.7.5 UAE Hormone Refractory Prostate Cancer Market Size, 2017-2028
7 Players Profiles
7.1 Astellas Inc
7.1.1 Astellas Inc Corporate Summary
7.1.2 Astellas Inc Business Overview
7.1.3 Astellas Inc Hormone Refractory Prostate Cancer Major Product Offerings
7.1.4 Astellas Inc Hormone Refractory Prostate Cancer Revenue in Global Market (2017-2022)
7.1.5 Astellas Inc Key News
7.2 Sanofi S.A
7.2.1 Sanofi S.A Corporate Summary
7.2.2 Sanofi S.A Business Overview
7.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Major Product Offerings
7.2.4 Sanofi S.A Hormone Refractory Prostate Cancer Revenue in Global Market (2017-2022)
7.2.5 Sanofi S.A Key News
7.3 Dendreon Corporation, Bayer AG
7.3.1 Dendreon Corporation, Bayer AG Corporate Summary
7.3.2 Dendreon Corporation, Bayer AG Business Overview
7.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Major Product Offerings
7.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Revenue in Global Market (2017-2022)
7.3.5 Dendreon Corporation, Bayer AG Key News
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Corporate Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Major Product Offerings
7.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer Revenue in Global Market (2017-2022)
7.4.5 Johnson & Johnson Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hormone Refractory Prostate Cancer Market Opportunities & Trends in Global Market
Table 2. Hormone Refractory Prostate Cancer Market Drivers in Global Market
Table 3. Hormone Refractory Prostate Cancer Market Restraints in Global Market
Table 4. Key Players of Hormone Refractory Prostate Cancer in Global Market
Table 5. Top Hormone Refractory Prostate Cancer Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hormone Refractory Prostate Cancer Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hormone Refractory Prostate Cancer Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hormone Refractory Prostate Cancer Product Type
Table 9. List of Global Tier 1 Hormone Refractory Prostate Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hormone Refractory Prostate Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hormone Refractory Prostate Cancer Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hormone Refractory Prostate Cancer Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hormone Refractory Prostate Cancer Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hormone Refractory Prostate Cancer Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hormone Refractory Prostate Cancer Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hormone Refractory Prostate Cancer Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2023-2028
Table 30. Astellas Inc Corporate Summary
Table 31. Astellas Inc Hormone Refractory Prostate Cancer Product Offerings
Table 32. Astellas Inc Hormone Refractory Prostate Cancer Revenue (US$, Mn), (2017-2022)
Table 33. Sanofi S.A Corporate Summary
Table 34. Sanofi S.A Hormone Refractory Prostate Cancer Product Offerings
Table 35. Sanofi S.A Hormone Refractory Prostate Cancer Revenue (US$, Mn), (2017-2022)
Table 36. Dendreon Corporation, Bayer AG Corporate Summary
Table 37. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Product Offerings
Table 38. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Revenue (US$, Mn), (2017-2022)
Table 39. Johnson & Johnson Corporate Summary
Table 40. Johnson & Johnson Hormone Refractory Prostate Cancer Product Offerings
Table 41. Johnson & Johnson Hormone Refractory Prostate Cancer Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Hormone Refractory Prostate Cancer Segment by Type in 2021
Figure 2. Hormone Refractory Prostate Cancer Segment by Application in 2021
Figure 3. Global Hormone Refractory Prostate Cancer Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hormone Refractory Prostate Cancer Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hormone Refractory Prostate Cancer Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hormone Refractory Prostate Cancer Revenue in 2021
Figure 8. By Type - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 12. US Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 16. Germany Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 17. France Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 24. China Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 28. India Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 30. Brazil Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hormone Refractory Prostate Cancer Revenue Market Share, 2017-2028
Figure 33. Turkey Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hormone Refractory Prostate Cancer Revenue, (US$, Mn), 2017-2028
Figure 37. Astellas Inc Hormone Refractory Prostate Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sanofi S.A Hormone Refractory Prostate Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Johnson & Johnson Hormone Refractory Prostate Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
